Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.

Blood Adv · 2022 · PMC9631687 · PMID 35439293

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients treated with R-B were older, had slightly worse performance status, had a greater proportion with Ki67 ≥ 30%, and showed a trend toward higher MIPI risk ( Table 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.